This could be due to the fact that most advanced malignant tumors produce multiple angiogenic factors, and so targeting only angiopoietins (in TekdeltaFc treated tumors) or only VEGF (in LDM-CTX-treated tumors) may not be adequate for complete tumor control [8, 28, 49, 50]. This evidence concerns the gene VEGFA and cancer.